YC W21 · Active

Valink Therapeutics

Discovering bispecific antibody drug-conjugates (BsADC) against cancer

Class: Winter 2021
Status: Active
Industry: Healthcare
Location: Boston, MA, USA
Team size: 15

Website

https://www.valinktx.com/

About

Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.